NASDAQ:CYCNCyclerion Therapeutics Stock Price, Forecast & News

Cyclerion Therapeutics' stock was trading at $2.90 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CYCN shares have increased by 102.4% and is now trading at $5.87. View which stocks have been most impacted by Coronavirus.

Cyclerion Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for Cyclerion Therapeutics.

Cyclerion Therapeutics Inc (NASDAQ:CYCN) announced its quarterly earnings data on Monday, May, 4th. The company reported ($0.73) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.87) by $0.14. The firm earned $1.01 million during the quarter. Cyclerion Therapeutics had a negative net margin of 1,917.30% and a negative return on equity of 96.31%. View Cyclerion Therapeutics' earnings history.

News stories about CYCN stock have been trending very negative this week, according to InfoTrie. The research group identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cyclerion Therapeutics earned a news sentiment score of -3.3 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news about Cyclerion Therapeutics.

Cyclerion Therapeutics saw a decrease in short interest in June. As of June 15th, there was short interest totaling 990,200 shares, a decrease of 15.4% from the May 31st total of 1,170,000 shares. Based on an average daily trading volume, of 241,200 shares, the days-to-cover ratio is currently 4.1 days. Currently, 4.3% of the shares of the company are sold short. View Cyclerion Therapeutics' Current Options Chain.

Some companies that are related to Cyclerion Therapeutics include Neoleukin Therapeutics (NLTX), Radius Health (RDUS), DiaMedica Therapeutics (DMCAF), Vanda Pharmaceuticals (VNDA), Stemline Therapeutics (STML), Molecular Templates (MTEM), Ardelyx (ARDX), AnaptysBio (ANAB), Corbus Pharmaceuticals (CRBP), Collegium Pharmaceutical (COLL), Atreca (BCEL), NextCure (NXTC), Crinetics Pharmaceuticals (CRNX), Kala Pharmaceuticals (KALA) and Legend Biotech (CALT). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cyclerion Therapeutics investors own include Ovid Therapeutics (OVID), Galmed Pharmaceuticals (GLMD), Lexicon Pharmaceuticals (LXRX), Onconova Therapeutics (ONTX), Opko Health (OPK), VBI Vaccines (VBIV), vTv Therapeutics (VTVT), Abeona Therapeutics (ABEO), ACADIA Pharmaceuticals (ACAD) and Agenus (AGEN).

Cyclerion Therapeutics trades on the NASDAQ under the ticker symbol "CYCN."

Shares of CYCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CYCN stock can currently be purchased for approximately $5.87.

Cyclerion Therapeutics has a market capitalization of $162.92 million and generates $4.51 million in revenue each year.

The official website for Cyclerion Therapeutics is www.cyclerion.com.

Cyclerion Therapeutics' mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The company can be reached via phone at 857-327-8778 or via email at [email protected]